Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-10 12:41 pm Purchase | 13G | Intellia Therapeutics, Inc. NTLA | ARK Investment Management LLC | 9,420,782 11.2% | 1,503,900 (+19.00%) | View |
| 2023-02-09 11:22 am Purchase | 13G | Intellia Therapeutics, Inc. NTLA | VANGUARD GROUP INC | 7,810,226 9.28% | 1,367,871 (+21.23%) | View |
| 2023-02-09 11:18 am Sale | 13G | Intellia Therapeutics, Inc. NTLA | FMR LLC | 2,421,952 2.879% | -1,455,820 (-37.54%) | View |
| 2023-01-25 10:36 am Purchase | 13G | Intellia Therapeutics, Inc. NTLA | BlackRock Inc. BLK | 7,254,921 8.7% | 1,634,545 (+29.08%) | View |
| 2022-02-14 06:05 am Sale | 13G | Intellia Therapeutics, Inc. NTLA | Nikko Asset Management Americas Inc. | 2,753,903 3.7% | -2,350,459 (-46.05%) | View |
| 2022-02-11 4:06 pm Purchase | 13G | Intellia Therapeutics, Inc. NTLA | REGENERON PHARMACEUTICALS INC. REGN | 3,702,995 4.98% | 925,218 (+33.31%) | View |
| 2022-02-10 08:17 am Purchase | 13G | Intellia Therapeutics, Inc. NTLA | VANGUARD GROUP INC | 6,442,355 8.66% | 1,311,158 (+25.55%) | View |
| 2022-02-09 2:38 pm Purchase | 13G | Intellia Therapeutics, Inc. NTLA | ARK Investment Management LLC | 7,916,882 10.64% | 274,430 (+3.59%) | View |
| 2022-02-09 09:19 am Purchase | 13G | Intellia Therapeutics, Inc. NTLA | FMR LLC | 3,877,772 5.21% | 3,719,166 (+2344.91%) | View |
| 2022-02-04 06:05 am Sale | 13G | Intellia Therapeutics, Inc. NTLA | Sumitomo Mitsui Trust Holdings Inc. | 2,753,903 3.7% | -2,350,459 (-46.05%) | View |
| 2022-02-03 4:41 pm Purchase | 13G | Intellia Therapeutics, Inc. NTLA | BlackRock Inc. BLK | 5,620,376 7.6% | 567,531 (+11.23%) | View |
| 2021-11-26 3:23 pm Sale | 13G | Intellia Therapeutics, Inc. NTLA | ARK Investment Management LLC | 7,642,452 10.4% | -3,549,218 (-31.71%) | View |
| 2021-02-16 4:33 pm Purchase | 13G | Intellia Therapeutics, Inc. NTLA | ARK Investment Management LLC | 11,191,670 17.4% | 2,450,238 (+28.03%) | View |
| 2021-02-11 4:24 pm Sale | 13G | Intellia Therapeutics, Inc. NTLA | Nikko Asset Management Americas Inc. | 5,104,362 7.94% | -318,856 (-5.88%) | View |
| 2021-02-10 11:03 am Purchase | 13G | Intellia Therapeutics, Inc. NTLA | VANGUARD GROUP INC | 5,131,197 7.98% | 1,606,998 (+45.60%) | View |
| 2021-02-05 06:10 am Sale | 13G | Intellia Therapeutics, Inc. NTLA | Sumitomo Mitsui Trust Holdings Inc. | 5,104,362 7.94% | -318,856 (-5.88%) | View |
| 2021-01-29 09:56 am Purchase | 13G | Intellia Therapeutics, Inc. NTLA | BlackRock Inc. BLK | 5,052,845 8.6% | 1,407,615 (+38.62%) | View |
| 2021-01-22 4:59 pm Sale | 13D | Intellia Therapeutics, Inc. NTLA | Novartis Institutes for BioMedical Research Inc. | 2,176,148 3.7% | -2,176,147 (-50.00%) | View |
| 2020-12-09 06:01 am Sale | 13G | Intellia Therapeutics, Inc. NTLA | Sumitomo Mitsui Trust Holdings Inc. | 5,423,218 9.18% | -1,755,302 (-24.45%) | View |
| 2020-12-08 4:26 pm Sale | 13G | Intellia Therapeutics, Inc. NTLA | Nikko Asset Management Americas Inc. | 5,423,218 9.18% | -1,755,302 (-24.45%) | View |